# Treace Medical Concepts, Inc.: overview

TMCI · Nasdaq · CIK 1630627 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tmci.md) · [Financials](/companies/tmci/financials.md) · [Filings](/companies/tmci/filings.md) · [Insiders](/companies/tmci/insiders.md)

Latest reported revenue: [$45.4m](/filings/0001630627-26-000018.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:Revenues, accession 0001630627-26-000018).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [45.1](/filings/0001193125-25-269556.md) | [68.7 d](/filings/0001193125-26-079167.md) | [52.6](/filings/0001193125-26-213322.md) | [47.4](/filings/0001630627-26-000018.md) | [50.2](/filings/0001193125-25-269556.md) | [62.5 d](/filings/0001193125-26-079167.md) | [47.2](/filings/0001193125-26-213322.md) | [45.4](/filings/0001630627-26-000018.md) |
| Gross margin | % | [80.1%](/filings/0001193125-25-269556.md) | [80.7% d](/filings/0001193125-26-079167.md) | [79.7%](/filings/0001193125-26-213322.md) | [79.7%](/filings/0001630627-26-000018.md) | [79.1%](/filings/0001193125-25-269556.md) | [80.6% d](/filings/0001193125-26-079167.md) | [79.3%](/filings/0001193125-26-213322.md) | [78.5%](/filings/0001630627-26-000018.md) |
| Operating margin | % | [(33.6%)](/filings/0001193125-25-269556.md) | [(0.3%) d](/filings/0001193125-26-079167.md) | [(29.6%)](/filings/0001193125-26-213322.md) | [(35.8%)](/filings/0001630627-26-000018.md) | [(31.2%)](/filings/0001193125-25-269556.md) | [(9.5%) d](/filings/0001193125-26-079167.md) | [(36.4%)](/filings/0001193125-26-213322.md) | [(33.0%)](/filings/0001630627-26-000018.md) |
| Net margin | % | [(34.1%)](/filings/0001193125-25-269556.md) | [(0.7%) d](/filings/0001193125-26-079167.md) | [(30.3%)](/filings/0001630627-26-000018.md) | [(36.7%)](/filings/0001630627-26-000018.md) | [(32.4%)](/filings/0001193125-25-269556.md) | [(15.0%) d](/filings/0001193125-26-079167.md) | [(38.1%)](/filings/0001630627-26-000018.md) | [(35.0%)](/filings/0001630627-26-000018.md) |
| Diluted EPS | $ per share | [(0.25)](/filings/0001193125-25-269556.md) | not reported | [(0.25)](/filings/0001193125-26-213322.md) | [(0.28)](/filings/0001630627-26-000018.md) | [(0.26)](/filings/0001193125-25-269556.md) | not reported | [(0.28)](/filings/0001193125-26-213322.md) | [(0.24)](/filings/0001630627-26-000018.md) |
| Free cash flow | $m | [(14.7) d](/filings/0001193125-25-269556.md) | [(7.3) d](/filings/0001193125-26-079167.md) | [0.7](/filings/0001193125-26-213322.md) | [(7.8) d](/filings/0001630627-26-000018.md) | [(11.9) d](/filings/0001193125-25-269556.md) | [(10.4) d](/filings/0001193125-26-079167.md) | [4.2](/filings/0001193125-26-213322.md) | [(6.9) d](/filings/0001630627-26-000018.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [94.4](/filings/0000950170-24-021228.md) | [142](/filings/0000950170-25-029029.md) | [187](/filings/0001193125-26-079167.md) | [209](/filings/0001193125-26-079167.md) | [213](/filings/0001193125-26-079167.md) |
| Gross margin | % | [82.1%](/filings/0000950170-24-021228.md) | [82.0%](/filings/0000950170-25-029029.md) | [81.2%](/filings/0001193125-26-079167.md) | [80.4%](/filings/0001193125-26-079167.md) | [79.8%](/filings/0001193125-26-079167.md) |
| Operating margin | % | [(17.5%)](/filings/0000950170-24-021228.md) | [(24.6%)](/filings/0000950170-25-029029.md) | [(27.5%)](/filings/0001193125-26-079167.md) | [(26.6%)](/filings/0001193125-26-079167.md) | [(25.5%)](/filings/0001193125-26-079167.md) |
| Net margin | % | [(21.8%)](/filings/0000950170-24-021228.md) | [(30.2%)](/filings/0000950170-25-029029.md) | [(26.5%)](/filings/0001193125-26-079167.md) | [(26.6%)](/filings/0001193125-26-079167.md) | [(27.7%)](/filings/0001193125-26-079167.md) |
| Diluted EPS | $ per share | [(0.43)](/filings/0000950170-24-021228.md) | [(0.77)](/filings/0000950170-25-029029.md) | [(0.81)](/filings/0001193125-26-079167.md) | [(0.90)](/filings/0001193125-26-079167.md) | [(0.93)](/filings/0001193125-26-079167.md) |
| Free cash flow | $m | [(19.9)](/filings/0000950170-24-021228.md) | [(45.5)](/filings/0000950170-25-029029.md) | [(46.0)](/filings/0001193125-26-079167.md) | [(48.8)](/filings/0001193125-26-079167.md) | [(29.5)](/filings/0001193125-26-079167.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tmci/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $25.3m | 6,364,000 |  | Unchanged |
| [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $13.2m | 3,305,100 |  | Added +90,807 |
| [GAGNON SECURITIES LLC](/funds/1125725.md) | 2026-06-30 | $12.1m | 3,029,543 |  | Reduced −2,172,343 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $8.1m | 2,028,479 |  | Added +566,972 |
| [Gagnon Advisors, LLC](/funds/1599466.md) | 2026-06-30 | $6.1m | 1,534,034 |  | New +1,534,034 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $6.0m | 1,497,673 |  | Added +435,833 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $5.5m | 1,380,021 |  | Reduced −1,960,002 |
| [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $5.3m | 1,328,592 |  | Added +1,063,659 |
| [CIBC Bancorp USA Inc.](/funds/1711924.md) | 2026-06-30 | $4.8m | 1,216,044 |  | Reduced −2,309 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $2.9m | 738,628 |  | Reduced −409,487 |

## Recent filings

[All 439 filings](/companies/tmci/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-07 | 07:12 ET | [10-Q](/filings/0001630627-26-000018.md) | Quarterly report, period 2026-06-30 | 0001630627-26-000018 |
| 2026-08-07 | 07:10 ET | [8-K](/filings/0001630627-26-000017.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001630627-26-000017 |
| 2026-05-20 | 17:30 ET | [8-K](/filings/0001630627-26-000014.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001630627-26-000014 |
| 2026-05-08 | 07:10 ET | [10-Q](/filings/0001193125-26-213322.md) | Quarterly report, period 2026-03-31 | 0001193125-26-213322 |
| 2026-05-08 | 07:05 ET | [8-K](/filings/0001193125-26-213267.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-213267 |
| 2026-04-09 | 07:00 ET | [8-K](/filings/0001630627-26-000010.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure | 0001630627-26-000010 |
| 2026-04-06 | 08:48 ET | [DEF 14A](/filings/0001630627-26-000005.md) | Proxy statement, period 2026-04-03 | 0001630627-26-000005 |
| 2026-02-27 | 07:14 ET | [10-K](/filings/0001193125-26-079167.md) | Annual report, period 2025-12-31 | 0001193125-26-079167 |
| 2026-02-27 | 07:10 ET | [8-K](/filings/0001193125-26-079163.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-079163 |
| 2026-01-13 | 08:54 ET | [8-K](/filings/0001193125-26-011177.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-011177 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-079167.md), filed Feb 27, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/83d25569-a9c0-4120-b35f-a91524734e58)

## About the filer

- CIK: 1630627
- Tickers: TMCI
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: FL
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 04:31 ET. No prices; not investment advice.